US targets Novo Nordisk's Ozempic and Wegovy for Medicare price talks
- Ozempic and Wegovy are among the 15 medications selected for Medicare price negotiations, as announced by the Biden Administration.
- Medicare spent $14.4 billion on Ozempic and Wegovy between November 2023 and October 2024, with nearly 2.3 million enrollees using them.
- The negotiations aim to lower drug costs for seniors and represent about a third of Medicare Part D spending, according to Health and Human Services Secretary Xavier Becerra.
- This marks the inclusion of 25 drugs in total for price negotiations, a process that has the potential to save billions for taxpayers and beneficiaries.
Insights by Ground AI
Does this summary seem wrong?
Coverage Details
Total News Sources0
Leaning Left26Leaning Right23Center66Last UpdatedBias Distribution57% Center
Bias Distribution
- 57% of the sources are Center
57% Center
L 23%
C 57%
R 20%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
